Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

This article updates advances in prostate cancer screening based on prostate-specific antigen, its derivatives, and human kallikrein markers. Many men are diagnosed with indolent disease not requiring treatment. Although there is evidence of a survival benefit from screening, the numbers needed to screen and treat remain high. There is risk of exposing men to the side effects of treatment for nonthreatening disease. A screening test is needed with sufficiently good performance characteristics to detect disease at an early stage so treatment may be offered with curative intent, while reducing the number of negative or unnecessary biopsies.

Original publication

DOI

10.1016/j.ucl.2014.01.003

Type

Journal article

Journal

Urol Clin North Am

Publication Date

05/2014

Volume

41

Pages

267 - 276

Keywords

Detection, Kallikreins, PSA, Prostate cancer, Screening, Diagnostic Errors, Early Detection of Cancer, Humans, Male, Mass Screening, Models, Statistical, Prognosis, Prostate-Specific Antigen, Prostatic Neoplasms